Inglasia provides you with the QP release for finished medicinal products intended for commercial supply within the European Union. This service delivers the legally required certification by a Qualified Person (QP), confirming that each batch complies with EU GMP standards and the approved Marketing Authorisation before it is placed on the EU market. Without QP certification, a finished drug product cannot be legally distributed for commercial sale in the EU.
Our role is strictly focused on commercial batch release. This is not a QP release of investigational medicinal products (IMPs), and it is not import licensing under a Manufacturer Importation Authorisation (MIA) license. It is the formal, legally binding certification that permits a finished medicinal product to enter commercial distribution across the EU.
Every batch undergoes structured documentation review, compliance verification, and final QP approval under a controlled, inspection-ready process.
Learn how this service integrates within our broader EU Import & Batch Release services and secure a compliant pathway for your commercial EU market supply.
QP release of a drug product is the legally required certification of a finished medicinal product before it can be supplied commercially within the European Union. A finished drug product is a completed dosage form — such as tablets, capsules, injectables, or biologics — that is packaged and ready for sale under an approved Marketing Authorisation.
Before any commercial batch can enter the EU market, a Qualified Person (QP) must certify that it has been manufactured and tested in accordance with EU GMP requirements and the registered Marketing Authorisation dossier. Without this certification, commercial distribution is not permitted. QP release acts as the final regulatory checkpoint between manufacturing and market supply.
This service is distinct from QP release of investigational medicinal products (IMPs) used in clinical trials, as IMP certification follows a separate regulatory pathway focused on clinical development, and not commercial sale.
QP release for drug products is specifically tied to commercial distribution. It ensures that each batch meets quality, safety, and regulatory standards before being placed on the EU market.
By securing a compliant QP certification, you protect your market authorisation, reduce regulatory risk, and enable lawful commercial supply across the European Union.
Inglasia follows a structured, commercially focused process to ensure that every finished batch is legally certified before EU market supply.
Each commercial batch begins with a detailed review of manufacturing records. We examine production documentation, in-process controls, and final packaging records to confirm that the batch was manufactured according to validated procedures.
All analytical testing results are verified against approved specifications. Certificates of analysis and laboratory data are reviewed to ensure the product meets quality, safety, and efficacy requirements.
Any deviations, changes, or investigations linked to the batch are assessed. The impact on product quality and regulatory compliance is evaluated before proceeding. Unresolved issues are addressed prior to certification.
The batch is confirmed against the approved Marketing Authorisation dossier. This ensures manufacturing processes, specifications, labeling, and packaging align with registered requirements.
Once compliance is confirmed, the Qualified Person formally certifies the batch under EU GMP. This certification is legally binding.
Following certification, the batch is authorised for commercial supply across the European Union, enabling lawful market distribution.
Contact us now
QP release of a drug product is governed by the EU Good Manufacturing Practice (EU GMP) framework, which sets the mandatory standards for manufacturing, testing, and quality control of medicinal products within the European Union. These regulations ensure that every commercial batch is produced consistently and meets approved quality specifications before entering the market.
Within this framework, Annex 16 defines the principles for batch certification and release by a Qualified Person. While Annex 16 outlines the responsibilities and certification expectations, the core obligation remains clear: no finished medicinal product may be placed on the EU market without a formal QP certification.
Certification confirms full compliance with the approved Marketing Authorisation. This includes verification that the batch was manufactured according to the registered dossier, tested in line with approved specifications, and produced within validated processes. Any deviations are assessed and resolved before certification.
Our Qualified Person carries legal accountability for each certified batch. By signing off on release, our QP confirms regulatory compliance under EU law. This accountability provides regulatory assurance, protects market authorisation holders, and ensures that only compliant medicinal products enter commercial distribution within the EU.
QP certification is the final regulatory checkpoint before a finished drug product enters the EU commercial supply chain. Once certified, the batch transitions from regulatory review to active market distribution, allowing wholesalers and distributors to place the product into lawful circulation.
This transition supports market launch readiness. Your certified batches can move forward without delay, enabling coordinated product launches, supply commitments, and commercial planning across EU Member States. Without QP release, commercial timelines are exposed to regulatory risk.
Our process also supports inspection readiness. Every certified batch is backed by structured documentation, traceable records, and documented assessments. This ensures that, if inspected, the certification pathway can be clearly demonstrated and justified under EU GMP requirements.
Risk mitigation is central to this stage. By verifying compliance before release, potential quality or regulatory issues are addressed early, reducing the likelihood of recalls, supply interruptions, or enforcement actions.
Each certified batch remains fully traceable, from manufacturing records through our QP approval. This regulatory traceability strengthens supply chain integrity and protects the Marketing Authorisation throughout commercial distribution in the European Union.
Inglasia delivers structured, legally compliant QP release of drug product services for companies supplying finished medicinal products to the EU market. Every batch is managed under our controlled, inspection-ready framework designed to protect your Marketing Authorisation and support uninterrupted commercial supply.
We provide formal QP certification for finished commercial batches intended for EU distribution. Each certification confirms compliance with EU GMP and the approved Marketing Authorisation. Our Qualified Persons assume full legal responsibility for every batch released.
Our team conducts a comprehensive review of batch manufacturing records, analytical testing data, and supporting quality documentation. We verify that production, testing, and packaging align with validated processes and registered specifications before certification proceeds.
All deviations, investigations, and changes associated with the batch are assessed for regulatory impact. We ensure that corrective actions are complete and that no unresolved quality concerns remain prior to release.
For companies with continuous EU supply, we provide ongoing oversight and structured release management. This supports predictable timelines, audit readiness, and regulatory continuity.
Learn how this service integrates into our broader EU Import & Batch Release services to secure a compliant and reliable pathway for commercial EU market entry.
Any company planning to place finished medicinal products on the EU market for commercial sale must obtain a QP release. Without certification by a Qualified Person, batches cannot be legally distributed in the European Union.
Our services are designed for companies that need reliable, legally compliant QP certification. This includes EU Marketing Authorisation Holders (MAHs) producing or supplying products within the EU, and non-EU MAHs relying on an EU-based Qualified Person to certify batches for lawful distribution.
Virtual pharmaceutical companies and biotech sponsors entering the commercial phase benefit from our expertise, ensuring each batch is certified without the need to maintain in-house QP resources. Contract Manufacturing Organisations (CMOs) also rely on our team to complete certification before batches reach the EU market.
For any company launching commercially in the EU, we provide a full QP release pathway, verifying, certifying, and approving every batch under EU GMP standards. Partner with Inglasia to secure your legally compliant, inspection-ready certification and confidently bring your products to the European market.
QP release for drug products is the legal certification of finished medicinal products intended for commercial supply in the EU. It confirms that each batch complies with EU GMP and the approved Marketing Authorisation before it can be distributed on the market.
Yes. Every finished medicinal product must be certified by a Qualified Person before it can be legally supplied within the European Union. Without QP release, commercial distribution is not permitted.
A finished drug product is a completed dosage form such as tablets, capsules, injectables, or biologics that is fully packaged and ready for sale. These products must undergo QP certification before entering the EU commercial supply chain.
QP release for drug products applies to commercial batches intended for market sale, while IMP certification applies to investigational medicinal products used in clinical trials. Each follows a different regulatory pathway and serves a different stage of product development.
QP release takes place after manufacturing, testing, and packaging are complete, and before the product is distributed in the EU. It acts as the final regulatory checkpoint prior to commercial market supply.
Ensure your finished medicinal products are certified, compliant, and ready for EU market supply with Inglasia as your EU batch release partner. Our experienced Qualified Persons provide legally binding QP certification for commercial drug products under a structured, inspection-ready framework aligned with EU GMP and your approved Marketing Authorisation.
Do not leave commercial distribution exposed to regulatory risk. Secure a controlled, accountable pathway from batch completion to lawful EU supply.
Contact our team to discuss your upcoming commercial batches or schedule a consultation to align your release timelines with EU regulatory requirements.
Discover how our EU Import & Batch Release services provide a complete, compliant route to EU market entry. Partner with Inglasia and release your commercial drug products with confidence, legal certainty, and full regulatory accountability.
